Vir Biotechnology (VIR) Other Non Operating Income (2018 - 2026)
Vir Biotechnology recorded quarterly Other Non Operating Income of -$254000.0 in Q1 2026, up 24.18% quarter-over-quarter from -$335000.0 in Q4 2025, and down 252.78% year-over-year from $166254.5 in Q1 2025.
Vir Biotechnology's Other Non Operating Income history runs 9 years deep, the most recent figure standing at -$254000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 252.78% year-over-year to -$254000.0; the TTM figure through Mar 2026 stood at -$591000.0 (up 70.54% YoY), while the FY2025 annual figure was -$409000.0, up 81.58% from the prior year.
- Other Non Operating Income came in at -$254000.0 for Q1 2026 at Vir Biotechnology, up from -$335000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $27.0 million in Q3 2022 to a low of -$26.2 million in Q4 2022.
- A 5-year average of -$447941.2 and a median of -$287000.0 in 2024 frame the typical range for Other Non Operating Income.
- On a YoY basis, Other Non Operating Income climbed as much as 42128.12% in 2022 and fell as far as 374000.0% in 2022.
- Vir Biotechnology's Other Non Operating Income stood at -$26.2 million in 2022, then surged by 94.33% to -$1.5 million in 2023, then surged by 65.93% to -$506000.0 in 2024, then soared by 33.79% to -$335000.0 in 2025, then gained by 24.18% to -$254000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$254000.0, -$335000.0, and -$228000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -254,000.00 |
| Dec 31, 2025 | -335,000.00 |
| Sep 30, 2025 | -228,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | -72,000.00 |
| Dec 31, 2024 | -506,000.00 |
| Sep 30, 2024 | -893,000.00 |
| Jun 30, 2024 | -535,000.00 |
| Mar 31, 2024 | -287,000.00 |
| Dec 31, 2023 | -1.49 Mn |
| Sep 30, 2023 | 882,000.00 |
| Jun 30, 2023 | -367,000.00 |
| Mar 31, 2023 | -8.02 Mn |
| Dec 31, 2022 | -26.19 Mn |
| Sep 30, 2022 | 27.03 Mn |
| Jun 30, 2022 | 691,000.00 |
| Mar 31, 2022 | 2.73 Mn |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | 64,000.00 |
| Jun 30, 2021 | 752,000.00 |
| Mar 31, 2021 | -10.25 Mn |
| Dec 31, 2020 | 2.44 Mn |
| Sep 30, 2020 | 2.62 Mn |
| Jun 30, 2020 | -2.90 Mn |
| Mar 31, 2020 | -7.07 Mn |
| Dec 31, 2019 | -1.81 Mn |
| Sep 30, 2019 | -2.66 Mn |
| Jun 30, 2019 | -447,000.00 |
| Mar 31, 2019 | -145,000.00 |
| Dec 31, 2018 | -198,000.00 |
| Sep 30, 2018 | 178,000.00 |